PT Medco Energi Internasional Tbk, (MEDC) Fair Value & Analysis
Energy · ID · Market cap 30.1T IDR
Analysis
PT Medco Energi Internasional Tbk, (MEDC) currently trades at 1,115 IDR, while our model-based Fair Value estimate is 1,795 IDR — implying the stock looks roughly 61.0% undervalued today. We read business quality at 91/100 (high quality), in the Energy sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
PT Medco Energi Internasional Tbk, together with its subsidiaries, explores for and produces oil and gas in Indonesia, Asia, Africa, the Middle East, and the United Kingdom. It operates through Exploration and Production of Oil and Gas; Services; Power; Chemicals; and Trading segments. The company operates an independent power producer in the gas, geothermal, and other renewables sectors, as well as manages a portfolio of onshore and offshore assets in the Middle East, Africa, and the Asia Pacific. It is also involved in copper and gold mining operations in Sumbawa and Nusa Tenggara; and providing operation and maintenance services, and support services for oil and gas activities. The company was formerly known as PT Medco Energi Corporation and changed its name to PT Medco Energi Internasional Tbk in 2000. The company was founded in 1980 and is headquartered in Jakarta, Indonesia. PT Medco Energi Internasional Tbk operates as a subsidiary of Pt Medco Daya Abadi Lestari.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.